We are live on ! Find out more

Tevogen Inc

TVGN

Market cap $48.9M

7.51 USD

+0.15

2.04%

At close Updated Sep 14, 4:00 PM EDT

1 day

2.04%

5 days

2.6%

1 month

9.32%

3 months

-25.05%

6 months

34.59%

Year to date

-58.71%

1 year

-82.17%

5 years

-98.49%

10 years

-98.49%

About: Tevogen Inc is a healthcare enterprise engaged in biotechnology, artificial intelligence and technology, and healthcare services. Its operations focus on the development of biotechnology products, AI- and technology-based healthcare solutions, and healthcare service initiatives.

Employees: 18

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Tevogen Bio Holdings Inc. Becomes Tevogen Inc.

WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval by its Board of Directors.

Tevogen Bio Holdings Inc. Becomes Tevogen Inc.

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced that its 2026 Annual Meeting of Stockholders (the “Annual Meeting)” is scheduled for Monday, August 24, 2026.

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

Tevogen Announces Formation of a Healthcare Services Initiative

William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the formation of its healthcare services initiative, a strategic business area intended to support the Company's evolution into a broader, revenue-generating healthcare enterprise.

Tevogen Announces Formation of a Healthcare Services Initiative

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue.

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a Management Services Organization (“MSO”).

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen highlights improved operating performance, disciplined capital allocation, pipeline growth, and evaluation of revenue-generating acquisitions.

Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private investment in public equity (the “PIPE”) financing with existing investor The Patel Family, LLP for gross proceeds of $3 million.

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including the near completion of its PredicTcell™ training algorithm and early steps toward commercial readiness.

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devices Target CRO operates across 20+ countries, providing global clinical development capabilities WARREN, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it is in advanced-stage evaluation of a niche contract research organization (CRO) with multi-country operations and established relationships across oncology, rare diseases, and medical devices.

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market.

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

See News Rankings

Price charts implemented using Lightweight Charts™